Related Experiment Video
Updated: May 27, 2025

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
Published on: June 2, 2015
Low-Dose Sublingual Ketamine for the Treatment of Raynaud's Phenomenon
1Department of Psychiatry, University of Colorado School of Medicine, Colorado Springs, USA.
Abstract:
Raynaud's phenomenon is a vascular disorder characterized by episodic vasospasm of small arteries, primarily affecting the hands and feet. Standard treatment strategies typically include lifestyle modifications to avoid cold exposure and stress, alongside pharmacological interventions aimed at increasing blood flow and reducing vascular constriction. Ketamine, an FDA-approved anesthetic since 1970, exhibits analgesic and vasodilatory properties that may enhance perfusion. This case report describes a woman with primary Raynaud's phenomenon whose symptoms improved significantly during treatment with low-dose sublingual ketamine prescribed for treatment-resistant depression. Further research into the use of this safe and inexpensive medicine as a treatment for Raynaud's phenomenon is recommended.
Related Concept Videos
Drug Delivery: Enteral Route
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Antihypertensive Drugs: Vasodilators
Parenteral Anesthetics: Overview

